Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 8, 2013, Pages 747-755

  Lu, Cui Cui ^a   Xu, Ying Qi ^a   Wu, Ji Chao ^a   Hang, Peng Zhou ^a   Wang, Yan ^a   Wang, Chen ^a   Wu, Jian Wei ^a   Qi, Jian Cui ^a   Zhang, Yong ^a   Du, Zhi Min ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin; CaMKII; Cardiac hypertrophy; NFAT; Vitexin

Indexed keywords

CALCINEURIN; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; ISOPRENALINE; VITEXIN; APIGENIN; CALCINEURIN INHIBITOR; CARDIOTONIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; LUNG WEIGHT; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; DRUG EFFECTS; HEART MUSCLE CELL; METABOLISM; NEWBORN; PRESSURE; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; APIGENIN; CALCINEURIN; CALCINEURIN INHIBITORS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; ISOPROTERENOL; MALE; MICE; MYOCYTES, CARDIAC; PRESSURE; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84880263683     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0873-0     Document Type: Article

References (46)

1. Anderson ME (2005) Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 106:39-55
2. Anderson ME, Brown JH, Bers DM (2011a) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51:468-473
3. Anderson ME, Brown JH, Bers DM (2011b) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51:468-473
4. Asakawa M, Komuro I (2001) Cardiac hypertrophy and calcium signaling. Clin Calcium 11:424-428
5. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, Maier LS, Olson EN (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106(7):2342-7
6. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128:191-227
7. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD (2002) Impaired cardiac hypertrophic response in calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A 99:4586-4591
8. Cave A, Grieve D, Johar S, Zhang M, Shah AM (2005) NADPH oxidasederived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond, B, Biol Sci 360:2327-2334
9. Cheng J, Xu L, Lai D, Guilbert A, Lim HJ, Keskanokwong T, Wang Y (2012) CaMKII inhibition in heart failure, beneficial, harmful, or both. Am J Physiol Heart Circ Physiol 302:H1454-1465
10. Dong LY, Chen ZW, Guo Y, Cheng XP, Shao X (2008) Mechanisms of vitexin preconditioning effects on cultured neonatal rat cardiomyocytes with anoxia and reoxygenation. Am J Chin Med 36:385-397
11. Dong L, Fan Y, Shao X, Chen Z (2011) Vitexin protects against myocardial ischemia/reperfusion injury in Langendorff-perfused rat hearts by attenuating inflammatory response and apoptosis. Food Chem Toxicol 49:3211-3216
12. Eom GH, Cho YK, Ko JH, Shin S, Choe N, Kim Y, Joung H, Kim HS, Nam KI, Kee HJ, Kook H (2011) Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation 123:2392-2403
13. Feron O, Salomone S, Godfraind T (1996) Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol 118:659-664
14. Gunther S, Baba HA, Hauptmann S, Holzhausen HJ, Grossmann C, Punkt K, Kusche T, Jones LR, Gergs U, Neumann J (2010) Losartan reduces mortality in a genetic model of heart failure. Naunyn Schmiedebergs Arch Pharmacol 382:265-278
15. Gupta S, Das B, Sen S (2007) Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antioxid Redox Signal 9:623-652
16. Han JJ, Hao J, Kim CH, Hong JS, Ahn HY, Lee YS (2009) Quercetin prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Med Sci 71:737-743
17. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD (2001) Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103:670-677
18. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589-600
19. 2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. Biochem Biophys Res Commun 314:695-703
20. Kim JH, Lee BC, Kim JH, Sim GS, Lee DH, Lee KE, Yun YP, Pyo HB (2005) The isolation and antioxidative effects of vitexin from Acer palmatum. Arch Pharm Res 28(2):195-202
21. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M (2002) Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol 282:H1703-1708
22. Lim HW, De Windt LJ, Steinberg L, Taigen T, Witt SA, Kimball TR, Molkentin JD (2000) Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 101:2431-2437
23. 2+/calmodulin- dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest s119(5):1230-40
24. MacDonnell SM, Weisser-Thomas J, Kubo H, Hanscome M, Liu Q, Jaleel N, Berretta R, Chen X, Brown JH, Sabri A-K, Molkentin JD, Houser SR (2009) CaMKII negatively regulates calcineurin - NFAT signaling in cardiac myocytes. Circ Res 105:316-325
25. Martino E, Collina S, Rossi D, Bazzoni D, Gaggeri R, Bracco F, Azzolina O (2008) Influence of the extraction mode on the yield of hyperoside, vitexin and vitexin-2″-O-rhamnoside from Crataegus monogyna Jacq. (hawthorn). Phytochem Anal 19:534-540
26. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228
27. 2+ uptake by cyclosporin A. Br J Pharmacol 141:263-268
28. Obata K, Nagata K, Iwase M, Odashima M, Nagasaka T, Izawa H, Murohara T, Yamada Y, Yokota M (2005) Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Biophys Res Commun 338:1299-1305
29. Oka T, Komuro I (2008) Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 72(A):A13-16
30. 2+-mediated calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 381(2):137-45
31. Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269-280
32. Rosca MG, Tandler B, Hoppel CL (2012) Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol
33. Sabri A, Hughie HH, Lucchesi PA (2003) Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid. Redox Signal 5:731-740
34. Saito T, Fukuzawa J, Osaki J, Sakuragi H, Yao N, Haneda T, Fujino T, Wakamiya N, Kikuchi K, Hasebe N (2003) Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol 35:1153-1160
35. Selvetella G, Lembo G (2005) Mechanisms of cardiac hypertrophy. Heart Fail Clin 1:263-273
36. Sun B, Huo R, Sheng Y, Li Y, Xie X, Chen C, Liu H-B, Li N, Li C-B, Guo W-T, Zhu J-X, Yang B-F, Dong D-L (2012) Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension 61(2):352-60
37. Vicencio JM, Estrada M, Galvis D, Bravo R, Contreras AE, Rotter D, Szabadkai G, Hill JA, Rothermel BA, Jaimovich E, Lavandero S (2011) Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications. Mini Rev Med Chem 11:390-398
38. Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, Song HX, Du ZM, Liu Y (2012) Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn Schmiedebergs Arch Pharmacol 385:823-831
39. Weiss CS, Hagenmuller M, Pichler M, Munz S, Ochs M, Buss SJ, Bekeredjian R, Katus HA, Hardt SE (2010) Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. Naunyn Schmiedebergs Arch Pharmacol 381:285-295
40. Wilkins BJ, Molkentin JD (2004) Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:1178-1191
41. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD (2002) Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22(21):7603-7613
42. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118
43. Wu Y, Gu YM (2007) Effect of EGb and quercetin on culture neonatal rat cardiomyocytes hypertrophy and mechanism. Zhongguo Ying Yong Sheng Li Xue Za Zhi 23:138-142
44. Yang SH, Liao PH, Pan YF, Chen SL, Chou SS, Chou MY (2012) The novel p53-dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells. Phytother Res doi: 10.1002/ptr.4841
45. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME (2005) Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11(4):409-17
46. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y, Komuro I (2001) Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104:97-101